William D. Waddill Sells 4,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director William D. Waddill sold 4,000 shares of Protagonist Therapeutics stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $54.25, for a total value of $217,000.00. Following the sale, the director now directly owns 13,130 shares of the company’s stock, valued at approximately $712,302.50. This represents a 23.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Protagonist Therapeutics Stock Down 0.8 %

Shares of PTGX stock opened at $52.65 on Friday. The stock has a market cap of $3.23 billion, a PE ratio of 19.79 and a beta of 2.34. The business has a 50-day simple moving average of $41.21 and a 200-day simple moving average of $42.62. Protagonist Therapeutics, Inc. has a 52-week low of $24.22 and a 52-week high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Friday, February 21st. The company reported $1.98 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $2.07. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The firm had revenue of $170.64 million during the quarter, compared to analyst estimates of $56.65 million. Sell-side analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Protagonist Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Bank of Montreal Can increased its stake in shares of Protagonist Therapeutics by 4.5% in the 4th quarter. Bank of Montreal Can now owns 6,250 shares of the company’s stock valued at $241,000 after purchasing an additional 270 shares in the last quarter. Maryland State Retirement & Pension System increased its stake in shares of Protagonist Therapeutics by 1.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company’s stock valued at $779,000 after purchasing an additional 278 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Protagonist Therapeutics by 10.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock valued at $121,000 after purchasing an additional 295 shares in the last quarter. Louisiana State Employees Retirement System increased its stake in shares of Protagonist Therapeutics by 1.1% in the 4th quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company’s stock valued at $1,112,000 after purchasing an additional 300 shares in the last quarter. Finally, KBC Group NV increased its stake in Protagonist Therapeutics by 54.4% during the 4th quarter. KBC Group NV now owns 2,093 shares of the company’s stock worth $81,000 after buying an additional 737 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Wall Street Analysts Forecast Growth

PTGX has been the subject of a number of research reports. JMP Securities reaffirmed a “market outperform” rating and set a $58.00 price target on shares of Protagonist Therapeutics in a research report on Friday, February 7th. StockNews.com cut Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. BTIG Research set a $73.00 price target on Protagonist Therapeutics in a research report on Monday, March 3rd. Wedbush reaffirmed an “outperform” rating and set a $70.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, March 11th. Finally, Truist Financial boosted their price objective on Protagonist Therapeutics from $60.00 to $76.00 and gave the company a “buy” rating in a report on Tuesday, March 11th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $62.56.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.